Massachusetts General Hospital: Hepatitis C trials
The registry lists 14 Hepatitis C studies with Massachusetts General Hospital as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 1Phase 2 1Phase 4 10No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/PibrentasvirTerminatedNCT04515797Phase 4Results posted
- Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung TransplantTerminatedNCT03625687Phase 4Results posted
- DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart TransplantTerminatedNCT03208244Phase 4Results posted
- DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver TransplantTerminatedNCT03208127Phase 4Results posted
- Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis CCompletedNCT02946034Phase 4Results posted
- Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)TerminatedNCT02503735Not applicableResults posted
- Sonoelastography: Ultrasound Method to Measure Liver FibrosisCompletedNCT01747772Not applicableResults posted
- Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis AccessWithdrawnNCT04614142Phase 4
- HCV + to HCV - Kidney TransplantWithdrawnNCT04320290Phase 4
- HCV Post-Exposure Prophylaxis for Health Care WorkersWithdrawnNCT03313414Phase 4
- Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney TransplantWithdrawnNCT03093740Phase 4
- Hepatitis C Virus Post-Exposure Prophylaxis for Health Care WorkersWithdrawnNCT01766115Phase 4
- A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV InfectionCompletedNCT01091077Phase 1
- Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C VirusCompletedNCT00403533Phase 2